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Abstract
Background: Recent advances in therapeutic options may prevent deterioration related to Huntington’s disease
(HD), even at the pre-symptomatic stage. Be that as it may, a well-characterized patient population is essential for
screening and monitoring outcome. Accordingly, the aim of this study was to describe the characteristics of a
Hungarian subpopulation of HD patients and mutation carriers diagnosed at the University of Szeged.
Methods: We conducted a search for International Classification of Diseases (ICD) code G10H0 in the local medical
database for the period of 1 January 1998 to 31 December 2018.
Results: We identified 90 HD cases (male: 45, female: 45) and 34 asymptomatic carriers (male: 15, female: 19). The
median age of onset was 45 years (range: 16–79). There were 3 cases of juvenile onset (3.3%), and 7 of late disease
onset (7.8%). The median repeat length was 43 (range: 36–70) for the pathological and 19 for the non-pathological
alleles (range: 9–35). 17.5% of the pathological alleles were in the decreased penetrance range, while 7% of non-
pathological alleles were intermediate.
Conclusions: The genetic and clinical features of the population examined in the present study were in line with
the previous Hungarian study, as well as with international literature. The exceptions were the higher ratio of
reduced penetrance and intermediate alleles.
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Background
Huntington’s disease (HD) is a hereditary neurodegenera-
tive disorder characterised by choreiform movements,
cognitive dysfunction, behaviour and mood problems [1–
4]. The worldwide prevalence of HD is estimated to be
2.71/100000, with a significantly higher prevalence (5.7/
100000) and incidence (0.11–0.8/100000) in Europe and
North America compared to Asian populations (preva-
lence: 0.4/100000, incidence: 0.046–0.16/100000) [2, 5].
HD is caused by a CAG trinucleotide repeat expansion
in the first exon of the HTT gene, located on chromo-
some 4p16.3, showing an autosomal dominant pattern of
inheritance [3, 6–10]. Repeat length of 26 or less is con-
sidered normal [3, 8, 11]. The repeats falling between 27
and 35 are referred to as intermediate alleles (or large
normal alleles), which are not considered to be patho-
genic, but, due to meiotic instability, they are prone to
expansion, often leading to the development of HD in
the next generation [3, 11, 12]. In some cases, however,
the presence of these alleles has been associated with
subtle HD-like symptoms [11, 13]. If the expansion ex-
ceeds 35 repeats, it becomes pathogenic, with the range
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36–39 showing decreased penetrance, and a length of 40
or longer showing full penetrance [3, 4, 8]. The age of
onset and the CAG repeat length of the pathological al-
lele shows a strong inverse correlation, though it is
widely debated in the literature whether repeat length by
itself can be used to accurately predict disease onset and
duration [3, 14]. Several studies suggest that the age of
onset can be influenced by other genetic factors, includ-
ing the length of the non-pathological allele [3, 15]. HD
is characterised by genetic anticipation, the phenomenon
that each successive generation demonstrates an earlier
age of onset. It is based on the meiotic instability of the
mutation, and is usually associated with paternal trans-
mission [3, 8].
The age of disease onset varies widely, the average be-
ing estimated between 30 and 50 years [1, 3, 4, 6, 7], but
it can occur during early childhood as well as over the
age of 60 [3, 4, 8]. Cases where the disease manifests it-
self before the age of 20 are called juvenile type HD,
whereas cases presenting symptoms after the age of 60
(in some papers, after the age of 50), are termed late on-
set HD [8, 9, 16–19]. Juvenile HD accounts for approxi-
mately 5% of all HD cases, and are usually characterised
by large repeat numbers and paternal transmission [19,
20]. Some of these patients present atypical symptoms
like rigidity, brady-hypokinesis, postural instability and
dysarthria, a phenotype referred to as the Westphal-
variant [21]. The frequency of late-onset HD varies
widely in different studies with a range between 4.4–25%
[16, 22]. In these cases, the course of the disease tends
to be mild, and repeat lengths are usually below 50 [16,
22]. Regarding disease course, HD is a progressive con-
dition, resulting in death within 10–20 years after the
first appearance of symptoms [9]. Juvenile onset is asso-
ciated with shorter and late onset with longer disease
duration [3, 20].
The aim of the current study is to evaluate the charac-
teristics of genetic and clinical features of a Hungarian
subpopulation of HD patients and asymptomatic car-
riers, and to compare the obtained results with those of
a previously published study from the same university in
1999 [10], as well as with available international litera-
ture data.
Methods
We performed a search for International Classification
of Diseases (ICD) code G10H0 in the electronic medical
database of the Department of Neurology, University of
Szeged, Hungary, for the period between 1 January 1998,
and 31 December 2018. We also reviewed the paper-
based medical archives of our out-patient unit for that
same time interval. Case assessment was conducted by
reviewing medical records of patient history and genetic
findings. HD was defined by the presence of a
pathological mutation in the HTT gene (CAG repeat
length of 36 or above) and related unequivocal neuro-
logical and/or psychiatric symptoms. A mutation carrier
was defined as having a pathological allele but no
evidence of clinical symptoms. Those who were first di-
agnosed as mutation carriers and developed symptoms
at a later time were placed in the HD patient group. Age
of onset was established by the first appearance of
neurologic or psychiatric symptoms which could be dir-
ectly associated with HD. Time of diagnosis was defined
as the earliest available date in the records when both
clinical symptoms and confirmatory genetic results were
present, or, when not available, the first reference in the
records as a genetically defined case. Regarding paternal
or maternal inheritance, the presence of HD in the af-
fected ancestors was based on clinical data. To put the
number of newly diagnosed HD cases into context, the
total number of patients seen in the in- and outpatient
units of our department was counted for each year in
the period of interest using the electronic medical data-
base of our department. We also assembled a control
group (n = 62, male: 32, female: 30), which, as illustrated
in Additional file 1, consisted of unaffected, asymptom-
atic relatives of HD patients who were tested at their
own request in order to determine potential carrier sta-
tus, and individuals, referred to our department for diag-
nostic purposes, who were suspected of suffering from
HD based on clinical presentation, but tested negative
for a pathological expansion in the HTT gene.
All statistical calculations were performed with the use
of the freely available R software (R Development Core
Team). We applied multiple linear regression models to
find out if there was a difference or interaction between
the different variables.
Results
Based on medical records from 1 January 1998 to 31
December 2018, we identified 90 cases of HD (male: 45,
female: 45) and 34 asymptomatic carriers (male: 15,
female: 19). In the HD patient group, there were a total
of 6 individuals – 3 male, 3 female – who were first
diagnosed as mutation carriers and later developed
symptoms. The median number of newly diagnosed HD
patients per year was 3, with a range of 1–8 new cases/
year, accounting for an average of 0.025% of all patients
seen in our department each year (range: 0.005–0.079%).
The core clinical features of the disease were present in
all individuals in the HD patient group. The medians
and ranges for age of onset are indicated in Table 1/A,
and a comparison of juvenile and late onset cases exam-
ined in this study is presented in Table 1/B.
One male patient with juvenile HD had a repeat length
of 52. He exhibited behavioural problems and learning
difficulties in early childhood and motor onset at the age
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of 18. A female patient, with a repeat length of 70, pre-
sented atypical symptoms such as rigidity, cognitive dys-
function, hypokinesis, postural instability, dysarthria and
dysphagia at the age of 16.
The first presenting signs of HD patients were deter-
mined from available documentation in 75 cases. The
distribution of these symptoms is indicated in Table 2.
The median time between disease onset and the date
of diagnosis was 3.5 years (range: 0–20 years). The fre-
quencies of all alleles in HD, carrier and control groups
are presented in Fig. 1.
Exact CAG repeat lengths of pathological alleles were
available in 86 HD cases (male: 42, female: 44) and in 34
carriers, whereas the sizes of normal alleles were known
in 75 HD patients and 31 carriers. The parameters (me-
dian, range) and distribution of pathological and non-
pathological alleles in each group are described in
Table 3. As indicated in Table 3, regarding alleles in the
non-expanded range, there is no statistical difference be-
tween HD, carrier and control groups.
The age of onset showed a strong inverse correlation
with the pathological CAG repeat length (F(1, 76) = 47.37;
R2 = 0.38; p < 0.001), whereas no statistically significant
correlation was found between the age of onset and the
size of non-expanded alleles (F(1, 69) = 1.94; R
2 = 0.013;
p = 0.17). When we investigated these alleles in the same
model, the results did not change (F(3, 67) = 16.86; R
2 =
0.41; p < 0.001), and there was no interaction between
the allele variables (p = 0.17; Fig. 2).
Alleles of decreased penetrance were identified in 9
carriers (26.5%, male: 2, female: 7) and 12 HD cases
(13.3%, male: 3, female: 9), representing 17.5% of patho-
logical alleles. In this group of HD patients, the mean
age of onset was 53.5 years (range: 39–78 years). Out of
these 21 individuals, an affected parent was known in 11
cases (mother: 5, father: 6).
Basic genetic and clinical information on symptomatic
control group individuals with two normal alleles is pre-
sented in Additional file 2.
We identified 16 individuals – 3 in the HD group and
13 in the control group – who carried intermediate
alleles. These intermediate alleles represented approxi-
mately 10.5% of control group alleles, 7% of all non-
pathological and 4.6% of all alleles assessed in this study.
The 13 individuals carrying intermediate alleles (male: 7,
female: 6) represented 21% of all controls. No individuals
with 2 intermediate alleles were found. Eight of these
controls, all of whom (as indicated in Additional file 1),
were referred to our department for diagnostic purposes,
presented with HD-like symptoms, such as chorea, peri-
oral dyskinesis, and cognitive decline (5 males with re-
peat lengths of 27, 28, 28, 30, 33, and 3 females with
repeat lengths of 28, 28, 35, respectively). Three of them
had additional symptoms, such as ataxia, dysphagia, dys-
arthria and convulsions. One person showed atypical
extrapyramidal signs (myoclonus, cervical dystonia). Evi-
dence for alternative diagnosis (alcohol and medication
abuse) was provided only in one of these cases. Only one
individual had a positive family history: a woman with
alleles of 15 and 35 repeat lengths, who presented with
minor signs of movement disorder showing no progres-
sion during follow-up examinations. Her mother was
Table 1 Age of onset in HD (A) and comparison of juvenile and late onset (B)
A) All Male Female
Available (n) 79 40 39
Median (years) 45 43.5 45
Range (years) 16–79 18–79 16–78
B) Juvenile onset Late onset
Number of cases (male/female) 3 (2/1) 7 (1/6)
Percent of all cases 3.3% 7.8%
Age of onset 16, 18, 19 years 61, 61, 62, 62, 71, 78, 79 years
CAG repeat length 70, 52, 59 repeats, respectively 45, 45, 40, 37, 39, 37, 40 repeats, respectively
Affected parent known 3 cases 2 cases
Parental transmission Paternal (3/3) Maternal (2/2)
Table 2 Distribution of first presenting symptoms in the HD patient group (available in 75 cases)
First symptom Motor = n (%) Cognitive = n (%) Psychiatric = n (%) Total = n (%)
Motor = n (%) 42 (46.7%) 17 (18.9%) 3 (3.3%) 62 (68.9%)
Cognitive = n (%) 17 (18.9%) 2 (2.2%) 0 (0%) 19 (21.1%)
Psychiatric = n (%) 3 (3.3%) 0 (0%) 11 (12.2%) 14 (15.6%)
Total = n (%) 62 (68.9%) 19 (21.1%) 14 (15.6%) 75 (100%)
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diagnosed with HD (there is no evidence of genetic con-
firmation) and she had several other relatives with simi-
lar symptoms.
Fifty-two HD patients were found to have a positive
family history. There were 25 patients with paternal and
27 with maternal inheritance. Regarding the carrier
group, evidence of an affected parent was found in 26
(14 with maternal and 12 with paternal inheritance) out
of 34 cases. Though the median age of onset was lower
in cases of paternal (38.5, range: 16–57 years) than in
that of maternal transmission (44.5, range: 24–79 years),
and the median repeat length was higher in cases of
paternal (46, range: 38–70) compared to maternal
inheritance (43, range: 37–58), the difference was not
statistically significant (p = 0.0612 for age of onset and
p = 0.1 for pathological allele size) (Figs. 3 and 4).
Discussion
In recent years, there have been major advances in
molecular therapeutic options for HD. As a prelude
to joining international clinical trials, the detailed
characterization of target patient populations is essential,
enabling clinicians to predict and better understand
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Fig. 1 Allele frequencies of HD (n = 86), carrier (n = 34) and control
groups (n = 62). As indicated, the majority of the pathological alleles
fall between 36 and 50 repeats, and those longer than 55 are very
rare. Regarding the non-pathological range, the most frequent
alleles are between 15 and 25 repeats, while intermediate alleles,
especially those between 30 and 35 are also rare
Table 3 Distribution of CAG repeat lengths in pathological and non-pathological ranges by group and gender






CAG repeats of pathological range (≥ 36)
N (male/female) 86 (42/44) 34 (15/19) – 120 (57/63) –
Median (male/female) 45 (45/43.5) 41 (42/41) – 43 (42/44) –
Range (male/female) 36–70 (38–59/36–70) 36–52 (36–52/36–49) – 36–70 (36–59/36/70) –
CAG repeats of decreased penetrance (36–39)
N (male/female) 12 (3/9) 9 (2/7) – 21 (5/16) –
Percent of respective group members 13.3% 26.5% – 17.5% –
CAG repeats of non-pathological range (< 36)
N (male/female)a 75 (34/41) 30 (13/17) 124 (64/60) – 229 (111/118)
Median (male/female) 18 (18/19) 19 (19/19) [62 (32/30)] – 19 (19/19)
Range (male/female) 9–28 (10–28/9–27) 14–24 (16–23/14–24) 20 (20/19)
10–35 (10–33/11/35)
– 9–35 (10–33/9–35)
CAG repeats of intermediate range (27–35)
N (male, female) 3 (2/1) 0 13 (7/6) – 16 (9/7)
Percent of respective group
members
4% 0 10.5% [21%] – 7%
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Fig. 2 Correlation between the age of onset and pathological CAG
repeat length in HD patients. An inverse correlation is presented in
the figure, indicating that higher repeat lengths are associated with
an earlier age of onset. It is also shown that the data are more
scattered along the lower range of the spectrum and less so in the
higher range, although the small number of cases with high repeat
numbers (55<) poses a limitation to such conclusions. The gray zone
represents the 95% confidence interval
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Accordingly, in this retrospective study, we aimed to char-
acterise 90 HD cases (male: 45, female: 45), and 34 carriers.
The median age of onset (45 years) was close to the
European Huntington’s Disease Network’s data for
Central Europe (47 years) but it was lower than those of
Northern (50 years) or Southern Europe (49 years) as
well as that of the United Kingdom (49 years) [4, 6, 9].
The ratio of juvenile onset cases (3.3%) was slightly
lower than the 5% described in other studies [16, 22].
All of these patients had a repeat length above 50 and a
positive family history where the affected parent was the
father. One patient with juvenile onset presented with
the atypical Westphal phenotype [21]. Seven patients
with late disease onset were identified, representing 7.8%
of all cases, which is well within the range (4.4–25%)
previously reported [16, 22]. Each of these patients had a
repeat length below 46, and evidence of an affected
parent was present in only 2 out of 7 cases.
The ratio of pure motor onset (47.6%) was similar to
the data of the European Huntington’s Disease Network
(48%), while psychiatric (12.2%) and cognitive (2.2%) on-
set was less frequent than reported in the same study
(19.6 and 8.4%, respectively). This difference might be
partly explained by the higher ratio of mixed onset cases
(22.2%) in the present study compared to the report of
the European Huntington’s Disease Network (13.2%) [6].
Compared to the previous study from Hungary (me-
dian: 43, range: 37–70) and the international literature
(median: 42–44, range: 36–121), we found that the
pathological repeat lengths of HD patients and asymp-
tomatic carriers was similar [6, 7, 10, 26, 27]. Alleles
with decreased penetrance were found in 9 carriers
(26.5%) and 12 HD patients (13.3%), representing ap-
proximately 17.5% of all pathological alleles found in this
study, which is higher than the data reported by the
European Huntington’s Disease Network (3.1% for all
participants, 1.8% for Central, 10% for Northern and
2.2% for Southern Europe) [6]. As expected, the median
age of onset (53.5 years) of patients in this range was
higher than that of the whole HD group (45 years) [12,
28]. The frequency of intermediate alleles, either in the
control group alleles (10.5%) or in all non-expanded al-
leles from the three groups (7%), was higher than those
reported from most populations (0.45–6%), the excep-
tions being the findings of 2 Brazilian cohorts with
frequencies of 7–8.7% [11, 13, 23, 29, 30]. There are sev-
eral reports associating intermediate alleles to HD-like
clinical and pathological findings, thus the assessment of
these alleles is gaining increased attention despite the
still controversial data [11, 12, 30]. In the current study,
we identified 8 individuals out of 13 controls with inter-
mediate alleles presenting symptoms similar to that of
HD, although lacking further clinical data or patho-
logical confirmation, it is unclear whether there is a
causative relationship between these alleles and the
presenting symptoms.
The median length of non-expanded CAG repeat
alleles (19) was similar to that found in the previous
Hungarian study (18) and those reported from other
Caucasian populations (17.1–19.3), but higher than in
Asian or African ethnic groups (16.2–17.7), [10, 23].
The strong inverse correlation between age of onset
and pathological repeat size was established in the
current study as well (R2 = 0.38; p < 0.001). However,
there was no significant association between the age of
onset and the length of the non-pathological allele. It
has been demonstrated that the expanded allele explains
about 66–67.3% of the variance in age of onset, whereas
the effect of the non-expanded allele is relatively small




















Fig. 3 Comparison of paternal (n = 25) and maternal (n = 27)
inheritance in term of age of onset. Though the difference is not
statistically significant, the figure illustrates that paternal transmission
tends to be associated with an earlier age of onset. The data are




























Fig. 4 Comparison of paternal (n = 25) and maternal (n = 27)
inheritance in term of pathological CAG repeat length. Though the
difference is not statistically significant, the figure illustrates a
tendency toward slightly higher repeat lengths in cases of paternal
transmission. The data are presented as median,
IQR, minimum-maximum
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proposed that the effect of the normal allele becomes
evident among individuals with large pathological repeat
lengths [15], the population of which accounts for only a
small proportion of patients in our study (25.6% with
repeat sizes above 46 and only 8% exceeding 50).
Although the lack of detailed clinical characterization
is a limitation of the study, the symptoms of HD, espe-
cially at an early stage, are rather diverse and aspecific,
therefore, a diagnosis of HD can only be established in
possession of correlating genetic evidence.
In conclusion, the genetic and clinical features of the
populations examined in the present study were in
accordance with the previous Hungarian study as well as
with international literature data, except for the higher
frequency of intermediate alleles and individuals with
reduced penetrance alleles. The presence of these alleles is
gaining importance in light of increasing evidence of
disease modifying genetic factors, such as the loss of inter-
ruption variants, which have been extensively investigated
in the past 2 years [31, 32], owing to developments in
analytic technologies. They are considered to cause CAG
repeat length underestimation with the currently, most
widely, used diagnostic methods. Additionally, some
authors suggest that these variants not only influence the
age of onset, but, in individuals carrying reduced pene-
trance alleles, they might play a major role in the mani-
festation of the disease [31, 32]. These factors have not yet
been thoroughly analysed in individuals carrying inter-
mediate alleles and presenting neurological symptoms,
which could serve as a target for future studies.
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